Daily Ards Research Analysis
Analyzed 9 papers and selected 3 impactful papers.
Summary
Three mechanistic studies advance ARDS biology by identifying actionable nodes across epithelial, endothelial, and neutrophil compartments. An epithelial SLC39A1-driven zinc–autophagy axis protects against lung injury, endothelial intracellular LRG1 triggers VE-cadherin ubiquitination and barrier failure, and neutrophil CD177 rewires glycolysis to fuel NLRP3 inflammasome activation—each accompanied by preclinical interventions that mitigate injury.
Research Themes
- Epithelial zinc–autophagy axis (SLC39A1) in AT2 cells
- Endothelial junction control via LRG1–MARCH2–VE-cadherin ubiquitination
- Neutrophil immunometabolism: CD177–glycolysis–NLRP3 inflammasome
Selected Articles
1. Epithelial SLC39A1 prevents acute lung injury through zinc-mediated transcriptional activation of autophagy in male mice.
SLC39A1 is upregulated in AT2 cells in male murine ALI and human ARDS. AT2-specific Slc39a1 deletion or zinc chelation worsened injury, while overexpression or zinc supplementation attenuated it; zinc could not rescue Slc39a1 deficiency. Mechanistically, zinc activates TFEB/TFE3/MITF to drive autophagy that protects AT2 cells, positioning SLC39A1 upstream of a protective zinc–autophagy pathway.
Impact: This work defines a druggable epithelial zinc–autophagy axis with genetic epistasis and human relevance, clarifying when zinc supplementation could be protective and when it may fail.
Clinical Implications: Suggests biomarker-guided zinc supplementation or AT2-targeted enhancement of SLC39A1–TFEB/TFE3/MITF signaling in ARDS. Patient stratification by epithelial SLC39A1/autophagy status and sex may be necessary before clinical trials.
Key Findings
- SLC39A1 is highly upregulated in AT2 cells in male murine ALI and in patients with ARDS.
- AT2-specific Slc39a1 deletion or zinc chelation exacerbates lung injury; overexpression or zinc supplementation attenuates it.
- Zinc activates TFEB/TFE3/MITF to drive autophagy in AT2 cells; Lc3b or Tfe3 deficiency abolishes zinc protection, placing SLC39A1 upstream of autophagy.
Methodological Strengths
- Multi-level validation: AT2-specific genetics, pharmacologic zinc manipulation, and epistasis analyses.
- Translational relevance with observations in human ARDS alongside murine models.
Limitations
- Findings are preclinical and predominantly in male mice; sex-specific effects require confirmation.
- Clinical dosing, safety, and efficacy of zinc or pathway modulators in ARDS remain untested.
Future Directions: Validate in both sexes and diverse ARDS etiologies, develop AT2-targeted delivery, identify biomarkers of SLC39A1/autophagy activity, and initiate early-phase biomarker-enriched trials.
Zinc transporters regulate intracellular zinc homeostasis, but their role in acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) remains underexplored. Here, we show that the zinc transporter SLC39A1 is highly upregulated in alveolar type II (AT2) cells from male murine ALI models and patients with ARDS. AT2-specific Slc39a1 deletion or zinc chelation exacerbates lung injury, whereas overexpression or zinc supplementation attenuates it. Notably, zinc supplementation fails to rescue Slc39a1-deficient mice, indicating SLC39A1 governs zinc uptake to control ALI. Zinc likely directly binds to and activates TFEB, TFE3, and MITF, inducing transcriptional activation of autophagy to eliminate damaged mitochondria and suppress apoptosis/pyroptosis in AT2 cells. Lc3b- or Tfe3-deficient mice show heightened lung injury, which remain unmitigated by zinc supplementation. Importantly, administration of AAV-shLc3b to AT2 Slc39a1-deficient mice did not further aggravate lung injury beyond that caused by either intervention alone. This epistatic relationship places SLC39A1 upstream of autophagy activation within a linear pathway. Collectively, we define an essential role for epithelial SLC39A1 in host defense against ALI/ARDS, which is mediated by a protective zinc-autophagy axis.
2. Intracellular LRG1 recruits MARCH2 to ubiquitinate and degrade endothelial VE-cadherin in septic lung injury.
Endothelial intracellular LRG1 is upregulated in sepsis and drives K48-linked polyubiquitination of VE-cadherin at K633 via MARCH2, causing proteasomal degradation and barrier failure. Genetic Lrg1 deletion and a PROTAC-based intervention preserved VE-cadherin, reduced hyperpermeability, and mitigated ALI in septic mice.
Impact: Reveals a previously unrecognized intracellular role of LRG1 in endothelial junction turnover and introduces a druggable axis (LRG1–MARCH2–VE-cadherin) amenable to PROTAC strategies.
Clinical Implications: Points to endothelial barrier restoration as a therapeutic avenue in sepsis-induced ALI/ARDS by inhibiting LRG1 or its interaction with MARCH2. Biomarker development around VE-cadherin turnover may guide patient selection.
Key Findings
- Endothelial intracellular LRG1 is upregulated in septic ALI and promotes VE-cadherin degradation.
- LRG1 recruits MARCH2 to catalyze K48-linked polyubiquitination of VE-cadherin at lysine 633, triggering proteasomal degradation.
- Lrg1 deletion or PROTAC-based pharmacologic intervention preserves VE-cadherin, reduces hyperpermeability, and mitigates ALI in septic mice.
Methodological Strengths
- Mechanistic precision pinpointing K48-linked ubiquitination site (K633) on VE-cadherin.
- Convergent genetic knockout and PROTAC-based pharmacology with in vivo endothelial permeability readouts.
Limitations
- Preclinical murine models without extensive validation in human tissues.
- Potential off-target and safety considerations for PROTAC approaches not addressed.
Future Directions: Validate in human endothelial cells and patient lung samples, develop selective LRG1/MARCH2 disruptors, and assess safety-pharmacokinetics of barrier-restoring agents.
Endothelial barrier dysfunction and consequent vascular injury are central contributors to acute lung injury (ALI) during sepsis. However, the underlying mechanisms remain incompletely understood, and effective therapeutic strategies targeting endothelial repair are still lacking. Here, we identify that intracellular leucine-rich α2-glycoprotein 1 (LRG1) in endothelial cells (EC) is significantly upregulated and directly promotes the degradation of vascular endothelial cadherin (VE-cadherin), a core adherens junction protein essential for maintaining vascular barrier integrity in septic ALI. Mechanistically, LRG1 recruits the E3 ubiquitin ligase membrane-associated ring-CH-type finger 2 (MARCH2) to catalyze K48-linked polyubiquitination of VE-cadherin at lysine 633, leading to its proteasomal degradation and subsequent endothelial barrier disruption. Genetic deletion of Lrg1 or pharmacological intervention with a proteolysis targeting chimera (PROTAC)-based degradation strategy significantly reduced VE-cadherin loss, alleviated endothelial hyperpermeability, and mitigated ALI in septic mice. Collectively, our study elucidates a previously unrecognized role of endothelial LRG1 in disrupting EC adherens junctions, providing novel insights into the pathogenesis of sepsis-associated injury and proposing a potential therapeutic strategy for sepsis-induced ALI and acute respiratory distress syndrome (ARDS).
3. CD177 Promotes NLR Inflammasome Activation in Acute Respiratory Distress Syndrome by Remodeling Neutrophil Glycolytic Metabolism.
CD177 orchestrates neutrophil glycolysis to potentiate NLRP3 inflammasome activation in ARDS. Knockdown dampens glycolysis and IL-1β release; exogenous lactate reverses this, and anti-CD177 antibodies reduce lung injury in mice, defining a targetable CD177–glycolysis–NLRP3 axis.
Impact: Links a clinically recognized neutrophil surface marker to metabolic control of inflammasome activation and demonstrates antibody-based mitigation of ARDS in vivo.
Clinical Implications: Supports development of anti-CD177 therapies and metabolic monitoring (e.g., lactate) to identify hyperinflammatory ARDS phenotypes responsive to neutrophil-targeted interventions.
Key Findings
- CD177 expression correlates with elevated lactate and IL-1β in bioinformatic analyses and animal models.
- CD177 knockdown reduces glycolytic flux and IL-1β secretion in vitro; lactate supplementation reverses these effects.
- Anti-CD177 antibody therapy reduces pulmonary edema and tissue injury in ARDS mouse models.
Methodological Strengths
- Integrated approach spanning bioinformatics, in vitro perturbation, and in vivo antibody intervention.
- Causal linkage via metabolic rescue (lactate) experiments.
Limitations
- Primarily preclinical with limited human validation beyond correlative analyses.
- Antibody dosing, timing, and safety profiles require systematic evaluation.
Future Directions: Validate CD177 as a biomarker in human ARDS cohorts, optimize anti-CD177 dosing/regimens, and explore combinatorial strategies with inflammasome inhibitors.
Acute respiratory distress syndrome (ARDS) is a high-mortality lung disorder driven by excessive neutrophil activation. While neutrophils are central to ARDS, the metabolic pathways fueling their inflammatory response remain unclear. This study identifies CD177 as a critical regulator of neutrophil glycolysis and NLRP3 inflammasome activation. Bioinformatics and animal models show that elevated CD177 correlates strongly with increased lactate and IL-1β levels. In vitro experiments demonstrate that CD177 knockdown reduces glycolytic flux and suppresses IL-1β release, a process reversed by lactate supplementation. Furthermore, treating ARDS mice with anti-CD177 antibodies significantly reduces pulmonary edema and tissue injury. These results establish the CD177-glycolysis-NLRP3 axis as a major driver of lung inflammation. Targeting this metabolic checkpoint provides a promising strategy for treating ARDS.